Fig. 3
From: SATB2 and CDX2 are prognostic biomarkers in DNA mismatch repair protein deficient colon cancer
a Kaplan–Meier survival curve comparing the disease-specific survival of patients with mismatch repair protein deficient colon cancer of all stages stratified by SATB2 expression. Patients with SATB2-negative tumors had reduced disease-specific survival compared with patients with SATB2-positive tumors (p = 0.001). b Kaplan–Meier survival curve comparing the disease-specific survival of patients with mismatch repair protein deficient colon cancer of all stages stratified by CDX2 expression. Patients with CDX2-negative tumors had reduced disease-specific survival compared with patients with CDX2-positive tumors (p = 0.001). c Kaplan–Meier survival curve comparing the disease-specific survival of patients with mismatch repair protein deficient colon cancer of all stages stratified by SATB2/CDX2 expression. Patients with SATB2 and/or CDX2-negative tumors had reduced disease-specific survival compared with patients with CDX2-positive/SATB2-positive tumors (p < 0.001). d Kaplan–Meier survival curve comparing the disease-specific survival of patients with mismatch repair protein deficient colon cancer with stage II or III disease stratified by SATB2/CDX2 expression. Patients with SATB2 and/or CDX2-negative tumors had reduced disease-specific survival compared with patients with CDX2-positive/SATB2-positive tumors (p < 0.001). e Kaplan–Meier survival curve comparing the disease-specific survival of patients with mismatch repair protein deficient SATB2 and/or CDX2-negative colon cancer of all stages with patients with mismatch repair protein proficient colon cancer of all stages. Patients with mismatch repair protein deficient SATB2 and/or CDX2-negative tumors had similar disease-specific survival compared with patients with mismatch repair protein proficient tumors (p = 0.7). f Kaplan–Meier survival curve comparing the disease-specific survival of patients with mismatch repair protein deficient SATB2 and/or CDX2-negative colon cancer with stage II or III disease with patients with mismatch repair protein proficient colon cancer with stage II or III disease. Patients with mismatch repair protein deficient SATB2 and/or CDX2-negative tumors had similar disease-specific survival compared with patients with mismatch repair protein proficient tumors (p = 0.5) in the stage II and stage III setting
